July 16th, 2014
HPS2-THRIVE: The Final Chapter in the Niacin Story?
Nicholas Downing, MD and Harlan M. Krumholz, MD, SM
Findings from HPS2-THRIVE raise uncomfortable questions for physicians.
September 19th, 2012
An Ad That Doesn’t Tell the Entire Story — Part 2: Niaspan
Harlan M. Krumholz, MD, SM
A print ad for Niaspan focuses only on how it raises HDL-cholesterol levels, with no mention of the lack of benefit in improving outcomes.
May 26th, 2011
NHLBI Stops the AIM-HIGH Trial of Niacin
Larry Husten, PHD
The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health) trial of niacin has been stopped early by the NHLBI. The trial was designed to test the addition of high-dose, extended-release niacin to statins in people at risk for CV events who had well-controlled LDL but low HDL and elevated […]
NEJM Journal Watch — Recent Cardiology Articles- Aprocitentan, a Newly Approved Drug for Resistant Hypertension
- Preventive PCI of Vulnerable Plaques Linked to Fewer Cardiac Events
- News from the ACC Scientific Sessions 2024
- Does the Coronary Sinus Reducer Decrease Ischemia and Angina in Patients with Stable Coronary Disease?
- Plozasiran Reduced Triglyceride Levels in Severe Hypertriglyceridemia